Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma

Nuclear Medicine Communications

Volumn 32, Issue 10, 2011, Pages 954-959

  Kim, Eui Young ^a   Kim, Tae Yong ^a   Kim, Won Gu ^a   Yim, Ji Hye ^a   Han, Ji Min ^a   Ryu, Jin Sook ^a   Hong, Suck Joon ^a   Yoon, Jong Ho ^a   Gong, Gyungyub ^a   Kim, Won Bae ^a   Shong, Young Kee ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

ablation success; differentiated thyroid carcinoma; radioiodine remnant ablation

Indexed keywords

IODINE 131; THYROID HORMONE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CERVICAL LYMPH NODE; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RADIATION DOSE; RADIATION THYROIDITIS; RETROSPECTIVE STUDY; SALIVARY GLAND DISEASE; SEX DIFFERENCE; THYROIDECTOMY; THYROIDITIS; TUMOR ABLATION; WHOLE BODY SCINTISCANNING; XEROSTOMIA;

ABLATION TECHNIQUES; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOTHERAPY DOSAGE; RECURRENCE; RETROSPECTIVE STUDIES; RISK; THYROID NEOPLASMS; THYROIDECTOMY; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052510506     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32834956ec     Document Type: Article

References (23)

1. Harris PE. The management of thyroid cancer in adults: a review of new guidelines. Clin Med 2002; 2:144-146. (Pubitemid 34498830)
2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668-3676. (Pubitemid 39089119)
3. Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988; 14:1063-1075.
4. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990; 71:414-424.
5. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19:741-760. (Pubitemid 20282665)
6. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97:418-428. (Pubitemid 24345593)
7. Pagano L, Klain M, Pulcrano M, Angellotti G, Pasano F, Salvatore M, et al. Follow-up of differentiated thyroid carcinoma. Minerva Endocrinol 2004; 29:161-174.
8. Roos DE, Smith JG. Randomized trials on radioactive iodine ablation of thyroid remnants for thyroid carcinoma-a critique. Int J Radiat Oncol Biol Phys 1999; 44:493-495. (Pubitemid 29258421)
9. Sherman SI. Thyroid carcinoma. Lancet 2003; 361:501-511. (Pubitemid 36173719)
10. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007; 92:28-38. (Pubitemid 46075005)
11. Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2009; 36:343-346.
12. Watkinson JC. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun 2004; 25:897-900. (Pubitemid 39180281)
13. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447-1463. (Pubitemid 32374886)
14. Degroot LJ, Reilly M. Comparison of 30-and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med 1982; 96:51-53. (Pubitemid 12205516)
15. Ramacciotti C, Pretorius HT, Line BR, Goldman JM, Robbins J. Ablation of nonmalignant thyroid remnants with low doses of radioactive iodine: concise communication. J Nucl Med 1982; 23:483-489. (Pubitemid 12070808)
16. Ramanna L, Waxman AD, Brachman MB, Tanasescu DE, Sensel N, Braunstein GD. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 1985; 10:791-795. (Pubitemid 16227084)
17. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med 1987; 12:500-502. (Pubitemid 17004386)
18. Johansen K, Woodhouse NJ, Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. J Nucl Med 1991; 32:252-254.
19. Leung SF, Law MW, Ho SK. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases. Br J Radiol 1992; 65:905-909.
20. Bal C, Padhy AK, Jana S, Pant GS, Basu AK. Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996; 77:2574-2580.
21. Utiger RD. Follow-up of patients with thyroid carcinoma. N Engl J Med 1997; 337:928-930. (Pubitemid 27408578)
22. Doi SA, Woodhouse NJ. Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. Clin Endocrinol (Oxf) 2000; 52:765-773. (Pubitemid 30409270)
23. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87:1499-1501. (Pubitemid 34615228)